Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1701 + bevacizumab + capecitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A **combination regimen** consisting of SHR-1701 (a bifunctional fusion protein targeting PD-L1 and TGF-β), **bevacizumab** (a monoclonal antibody against VEGF-A), **capecitabine** (an oral prodrug of fluorouracil), and **oxaliplatin** (a platinum-based chemotherapeutic agent) used primarily for the first-line treatment of **unresectable metastatic colorectal cancer**. SHR-1701 exerts dual antagonism—blocking PD-L1 to unleash antitumor immunity and sequestering TGF-β via the extracellular domain of TGFβ receptor II, mitigating immunosuppressive tumor microenvironment effects. Bevacizumab inhibits angiogenesis by blocking VEGF-A; capecitabine is metabolized to 5-fluorouracil, inhibiting thymidylate synthase, and oxaliplatin forms DNA crosslinks resulting in cytotoxicity. The combination demonstrates a **manageable safety profile and potent antitumor activity** with objective response rates approaching 60% in phase 2 studies for metastatic colorectal cancer[3].
- Brand names
- XELOX
- Other names
- SHR-1701 + BP102 + XELOX
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SHR-1701 + bevacizumab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1701 + bevacizumab + capecitabine + oxaliplatin.